China approves two-dose schedule for GSK’s cervical cancer drug

By Toby Hayes, portfolio manager, Trium Capital Unprecedented inflation has unleashed a wave of volatility that may have ended the longenshrined 60-40 portfolio model. And despite the optimistic assertions of

Written by Dr Daniel Koller, Head PM at BB Biotech The driving force for many new therapeutic approaches for drugs, yet with low stock market valuations – the biotech industry

Last week, it was reported that the UK government is planning to link non-executive rewards to the success of the company via performance fees to make the City of London

With the Bank of England predicting UK inflation will rise to 10% by the end of the year before going down again next year, CAMRADATA’s latest whitepaper on Inflation Protection

BlackRock’s MyMap range has marked its third anniversary with resilient performance since launch, despite market volatility in the wake of the COVID-19 pandemic and additional turbulence resulting from the conflict

Newton Investment Management Group, part of BNY Mellon Investment Management, has bolstered its multi-asset senior leadership team with the appointments of Paul Flood as Head of Mixed Assets Investment, and

Many of the boards of Europe’s largest financial services firms are underweight when it comes to the skills, experience, and level of diversity that investors say are important to them,

In a world characterized by lower growth and higher inflation – fueled by factors such as the war in Ukraine, ongoing supply chain disruptions and lingering COVID risks – investors

The JOHCM Global Opportunities Fund aims to provide investors with a return profile that captures much of the upside but with materially lower volatility than either the index or comparable